BioMarin to Buy Alesta for $275M Upfront, Gaining Oral HPP Candidate ALE1
BioMarin Pharmaceutical announced an agreement to acquire Alesta Therapeutics for $275 million in upfront cash, securing rights to ALE1, an orally active small molecule in Phase 1/2a testing for hypophosphatasia (HPP). The acquisition includes up to $215 million in milestone payments and will be funded from BioMarin's cash on hand. The transaction …